tbuckley/cabot-search huggingface dataset:
VENA CAVAL THROMBOSIS WITH POLYCYTHEMIA AND LEG ULCER
Authors: J A BOONE, H G SMITHY
Journal: Annals of Internal Medicine (1949)

Case Reports1 September 1949VENA CAVAL THROMBOSIS WITH POLYCYTHEMIA AND LEG ULCERJOHN A. BOONE, M.D., F.A.C.P., HORACE G. SMITHY, M.D.JOHN A. BOONE, M.D., F.A.C.P.Search for more papers by this author, HORACE G. SMITHY, M.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-31-3-513 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptThe first case of vena caval thrombosis associated with polycythemia was reported by Ragins and Coe in 1943.1 In their patient the polycythemia developed under observation subsequent to a thrombosis of both the superior and inferior vena cava. The patient did not recover and an autopsy disclosed the vena caval obstruction which had been suspected clinically. Before the thrombosis the hemoglobin was 85 per cent and the red blood count 4,900,000. After the thrombosis the hemoglobin rose to 100 per cent and the red blood count to 7,960,000.We wish to report a similar case which recovered and subsequently developed...Bibliography1. RAGINSCOE OBGC: Superior and inferior venae cavae thrombosis with polycythemia; report of a case, Ann. Int. Med., 1943, xix, 496-501. Google Scholar2. SMITHY HG: Complicating factors in the surgical management of varicose veins with special reference to interruption of sympathetic nerve impulses as an adjunct in treatment, Surgery, 1945, xvii, 590. Google Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: *Received for publication April 16, 1947.From the Departments of Medicine and Surgery, Medical College of South Carolina and Roper Hospital, Charleston, S. C.†Deceased. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byInferior Vena Cava Obstruction Clinical Manifestations, Diagnostic Methods, and Related ProblemsMORRIS E. MISSAL, M.D., F.A.C.P., JAMES A. ROBINSON, M.D., RONALD W. TATUM, M.D.The nephrotic syndrome following thrombosis of the inferior vena cava 1 September 1949Volume 31, Issue 3Page: 513-517KeywordsAutopsyBlood countsHemoglobinHospital medicineInferior vena cavaPolycythemiaSurgeryThrombosisUlcers ePublished: 1 December 2008 Issue Published: 1 September 1949 PDF downloadLoading ...
Abstract 9271: Late-Gadolinium Enhancement by Cardiac Magnetic Resonance Confers Additive Independent Prognostic Value in New-Presentation Idiopathic Dilated Cardiomyopathy
Authors: Darryl P Leong, Adhiraj Chakrabarty, Nicholas Shipp, Payman Molaee, Per L Madsen, Lucas Joerg, Amy Penhall, Rebecca Perry, Thomas Sullivan, Stephen G Worthley, Carmine G DePasquale, Prashanthan Sanders, Joseph B Selvanayagam
Journal: Circulation (2010)

Introduction: Myocardial fibrosis and dyssynchronous ventricular contraction are hallmarks of idiopathic dilated cardiomyopathy (DCM). Previous studies have focussed on well established DCM, howeve...
Response to brodalumab and ixekizumab, anti-interleukin-17-receptor antibodies for psoriasis: a critical appraisal
Authors: C. Leonardi
Journal: British Journal of Dermatology (2012)

Journal Article Response to brodalumab and ixekizumab, anti‐interleukin‐17‐receptor antibodies for psoriasis: a critical appraisal Get access C. Leonardi C. Leonardi Central Dermatology PC, 1034 S. Brentwood Blvd, Suite 600, St Louis, MO 63117, U.S.A. E‐mail: leonardi@centralderm.com Search for other works by this author on: Oxford Academic Google Scholar British Journal of Dermatology, Volume 167, Issue 4, 1 October 2012, Pages 714–715, https://doi.org/10.1111/bjd.12027 Published: 01 October 2012
Eosinophilic pustular folliculitis in patients with acquired immunodeficiency syndrome
Authors: Fred F. Soeprono, Roger A. Schinella
Journal: Journal of the American Academy of Dermatology (1986)

Eosinophilic pustular folliculitis is a rare disease. Highly unusual is its occurrence in three patients with acquired immunodeficiency syndrome (AIDS), described herein. This association may be the result of immunologic aberrations that are described in AIDS and may represent an abnormal reaction to skin saprophytes and dermatophytes. Eosinophilic pustular folliculitis is a rare disease. Highly unusual is its occurrence in three patients with acquired immunodeficiency syndrome (AIDS), described herein. This association may be the result of immunologic aberrations that are described in AIDS and may represent an abnormal reaction to skin saprophytes and dermatophytes.
Abstract 15949: The Inflammatory Niche and Aberrant Differentiation of Vascular Stem Cells in Ectopic Calcification of Atherosclerotic Plaque
Authors: Aleksandra Leszczynska, Aideen O’Doherty, Eric Farrell, Fergal O’Brien, Timothy O’Brien, Mary Murphy
Journal: Circulation (2014)

Mounting evidence suggests that vascular calcification is as an active cell controlled event. We hypothesized that in presence of inflammatory cytokines seen in atherosclerotic environment, a pericyte-like stem cells population, termed vessel derived stem cells (VSCs), and circulating mesenchymal stem cells (MSCs), contribute to the calcification of atherosclerotic plaque via endochondral ossification. VSCs from aortae of ApoE-/- mice and background C57Bl/6 mice were isolated and characterized. To assess their ability to form bone, cells were seeded onto collagen glycosaminoglycan scaffolds and primed chondrogenically in vitro followed by subcutaneous implantation in ApoE-/- and C57BL/6 mice for 8 weeks. ApoE-/- MSC and VSC constructs formed bone when implanted in C57BL/6 mice (Fig.1 and Table 1). Also, ApoE-/- MSC and ApoE-/- VSC constructs generated more mature bone in ApoE-/- mice (Fig.1) than C57BL/6 MSC and VSC constructs (Table 1). To interrogate the mechanism, the effect of proinflammatory cytokines associated with the atherosclerotic niche on chondrogenic differentiation in vitro was assessed. At 21 days following IL-6 treatment, ApoE-/- VSCs showed increased levels of Sox9, fibromodulin, type II collagen, aggrecan and alkaline phosphatase. That both MSCs and VSCs from the ApoE-/- atherosclerotic mice generate a more mature hypertrophic chondrocyte than cells from the C57BL/6 mice is a novel finding and suggests that the atherosclerotic environment may modulate the stem cell phenotype. Improved bone formation from ApoE-/- cells as well as in the ApoE-/- animals using wild type cells illustrated that the cell and environment are important for bone formation.
Abstract 17980: Evaluation of Attenuation Correction in Cardiac PET using PET/MR
Authors: Man Chun Jeffrey Lau, Richard Laforest, Houman Sotoudeh, Xingyu Nie, Shivak Sharma, Jonathan McConathy, Agus Priatna, Robert Gropler, Pamela Woodard
Journal: Circulation (2014)

Background: Simultaneous acquisition Positron Emission Tomography / Magnetic Resonance (PET/MR) is a new technology that has potential as a tool both in research and clinical diagnosis. However, cardiac PET acquisitions have not yet been fully validated using MR imaging for attenuation correction (AC). The goal of this study is to evaluate the feasibility of PET imaging using a standard 2-point Dixon VIBE (Volume Interpolated Breathhold Examination) MR sequence for attenuation correction. Materials and Methods: AC evaluation was performed in both phantoms and patients. A chest phantom containing heart and lung inserts was scanned by both PET/MR and PET/CT to assess the effect of the attenuation from the phased array coil, PET reconstruction accuracy, and the effect of the fixed attenuation u-value of the lungs. In addition, 30 patients underwent whole-body 18F-Fluorodeoxyglucose PET/CT (~60 min post-injection) followed by simultaneous cardiac PET/MR (~120 min post-injection). Results: Phantom study showed...
Abstract 271: Rapid Estrogen-Induced Cardioprotection Is Mainly Mediated by G-Protein--Coupled Estrogen Receptor 1 During Ischemia/Reperfusion
Authors: Jean Chrisostome Bopassa, Rong Lu, Harpreet Singh, Bjorn Olde, Andree Krust, L M Fredrik Leeb-Lundberg, Ligia Toro, Enrico Stefani
Journal: Circulation (2011)

Introduction: Numerous basic and clinical studies have demonstrated that 17β-estradiol (E2) has a protective effect on cardiovascular function. The long-term effects of E2 are mediated via classical estrogen receptors: alpha (ERα) and beta (ERβ) through genomic and non-genomic targets while rapid E2-induced protection seems to be mediated by the recent identified G-protein coupled estrogen receptor1 (GPER1). Hypothesis: We investigated the role of ERα, ERβ and GPER1 in mediating rapid E2-induced cardioprotection in male mice hearts subjected to ischemia/reperfusion (I/R) using wild type (WT) and specific knockout animals. Methods: Ventricles possess GPER1&gt;ERα&gt;ERβ mRNA levels quantified in absolute values with quantitative Real Time PCR. Isolated hearts from wild type (WT: C57BL/6NCrL), ERα -/- , ERβ -/- and GPER1 -/- were perfused using Langendorff apparatus with Krebs Henseleit buffer (control) or with the addition of E2 (40 nM). Hearts were subjected to 18 min global ischemia followed by 60 min reperfusion. Cardiac function was recorded during the entire experiment and myocardial infarct size measured by TTC staining at the end of the reperfusion. Mitochondria calcium retention capacity (CRC) required to induce the mitochondrial permeability transition pore opening (mPTP) opening was assessed and protein levels were measured by Western Blot in whole heart lysates after 10 min reperfusion. Results: In WT, ERα -/- and ERβ -/- , E2 treatment significantly improved cardiac functional recovery, reduced infarct size and improved mitochondrial CRC. However, E2-induced cardioprotective effects were completely absent in GPER1 -/- . Rapid E2 treatment induced up-regulation of GSK-3β, ERK 1/2 and PKC β II phosphorylation in WT mouse compared to control but not in GPER1 -/- . The reported results were statistically significant different with P&lt;0.05 and n=3-6. Conclusion: These results suggest that GPER1 plays a major role in mediating rapid E2-induced cardioprotection after I/R. E2 effects through GPER1 are associated with phosphorylation of GSK-3β, ERK 1/2 and PKC βII and inhibition of the mPTP opening.
Abstract 14036: An Algorithm to Guide Prognosis Based on the Combination of Peak VO <sub>2</sub> and V <sub>E</sub> -VCO <sub>2</sub> slope in Patients with HFrEF: The Henry Ford HospITal CardioPulmonary EXercise Testing (FIT-CPX) Project
Authors: Clinton A Brawner, Ali Shafiq, Heather A Aldred, Raakesh Hassan, Stephanie Vasko, Jonathan K Ehrman, Yelena Selektor, Christina Tita, Mauricio Velez, Celeste T Williams, David E Lanfear, Steven J Keteyian
Journal: Circulation (2014)

Many studies have reported the prognostic significance of peak oxygen consumption (VO 2 ) and V E -VCO 2 slope in patients with heart failure (HF). However, there are limited data stratifying risk based on a combination of these measures and how to best use them. Purpose: Describe 1 and 3-y event rates for the composite endpoint of mortality, left ventricular assist device (LVAD), or cardiac transplant (CT) based on the combined evaluation of peak VO 2 and V E -VCO 2 slope in patients with HF with reduced ejection fraction (≤ 40%; HFrEF). Methods: Patients (n= 1,116; 33% female; age= 54 ± 13 y) with a cardiopulmonary exercise test between 1997 and 2010 and confirmed HFrEF were identified. Endpoint data was obtained through 2011. Patients were grouped based on peak VO 2 (&lt; 12, 12 to18, and &gt; 18 mL/kg/min) and (V E -VCO 2 slope ≥ 34 or &lt; 34). Cumulative events were identified from life tables. Cox regression with adjustment for age, gender, ejection fraction, and beta-blocker therapy was used to calculate the hazard ratio for V E -VCO 2 slope ≥ 34 within each peak VO 2 group. Results: The 1 and 3-y event rates are shown in the Table. Among patients with a peak VO 2 &lt; 12, 1 and 3-y events were 23% and 44%, respectively. Within this group, V E -VCO 2 slope ≥ 34 represented more than twice the risk at both 1 y (HR 2.42, 95% CI 1.09, 5.38) and 3 y (HR 2.32, 95% CI 1.33, 4.05). Among patients with a peak VO 2 12 to 18, 1 and 3-y events were 14% and 30%, respectively. Within this group, a V E -VCO 2 slope ≥ 34 was associated with increased risk at both 1 y (HR 1.80, 95% CI 1.13, 2.87) and 3 y (HR 1.80, 95% CI 1.30, 2.50). Among patients with peak VO 2 &gt; 18, 1 and 3-y events were 2% and 10%, respectively, and V E -VCO 2 slope was not statistically associated with increased risk. Conclusion: Among patients with a peak VO 2 ≤ 18, V E -VCO 2 slope ≥ 34 further refines the risk for a composite endpoint of mortality, LVAD, or CT at both 1 and 3 y.
Clash of lifestyles
Authors: Biji T Kurien
Journal: BMJ (2003)

From BMJ USA 2003;April:222 

During my pre-doctoral studies in India (a former British colony), I heard an Indian speaker say, “What the Americans do inside the house (lavatory), we do outside; what they do outside (osculation, eating), we do inside.” A few years later, as a post-doctoral fellow in America, I could compare firsthand the differences in lifestyle between these two countries.

On arrival itself, I could see that the differences were monumental. The sheer opulence of America was an eye-opener. My journey into the differences began with a car ride, its driver sitting on the wrong …
A map for sequence analysis of the Arabidopsis thaliana genome
Authors: Marco Marra, Tamara Kucaba, Mandeep Sekhon, LaDeana Hillier, Robert Martienssen, Asif Chinwalla, Jye'mon Crockett, Jacqueline Fedele, Heather Grover, Christopher Gund, W. Richard McCombie, Ken McDonald, John McPherson, Nancy Mudd, Larry Parnell, Jacqueline Schein, Ryan Seim, Proteon Shelby, Robert Waterston, Richard Wilson
Journal: Nature Genetics (1999)
Abstract 1796: Novel triazole nucleoside inhibits heat shock factor 1 and androgen receptor to fight against prostate cancer
Authors: Yi Xia, Eliana Beraldi, Amina Zoubeidi, Ling Peng, Martin Gleave
Journal: Cancer Research (2014)

Abstract Prostate cancer is one of the most commonly diagnosed cancers and leading cause of cancer-related mortality in men in developed countries. While most patients initially respond to first-line androgen deprivation therapy (ADT), many become refractory to hormonal and other conventional therapies and eventually develop castration-resistant prostate cancer (CRPC) with time. CRPC is often characterized by the reactivation of androgen receptor (AR) and constitutes the most important therapeutic target in CRPC. It is known that AR is bound to heat shock protein (HSPs) complex to maintain its stable and mature conformation with high affinity to androgen. Targeting HSPs are therefore to result in perturbation of AR. Using a lead optimization process, we have recently identified a novel triazole nucleoside VM-1 which can down-regulate heat shock transcription factor 1 (HSF1), the dominant upstream transcriptional regulator for HSPs. The down-regulation of HSF1 by VM-1 leads to the simultaneous suppression of multiple HSPs and results in growth inhibition of various prostate cancer cells. Interestingly, VM-1 displays more potent antiproliferation activity in AR-positive LNCaP, C4-2 and 22RV-1 cells than AR-negative PC-3 cells. Our further studies have showed that VM-1 reduces the expression of AR and a panel of AR targeted genes as well as inhibits AR transactivation, which consequently leads to effective caspase-dependent apoptosis in LNCaP, C4-2 and 22RV-1 cells. Moreover, VM-1 arrests cell cycle of prostate cancer cells in AR-governed phase suggesting the potential functionality of this compound involved in the crosstalk between AR and cell cycle pathways. Taken together, the above data suggest the role of HSF1 in regulation of AR, and the inhibition on both HSF1 and AR contribute to the activity of VM-1 in prostate cancer cells. Therefore, VM-1 may serve as a novel structural motif in the search of anticancer candidates to fight against prostate cancer via inhibiting HSF1 and AR. Citation Format: Yi Xia, Eliana Beraldi, Amina Zoubeidi, Ling Peng, Martin Gleave. Novel triazole nucleoside inhibits heat shock factor 1 and androgen receptor to fight against prostate cancer. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 1796. doi:10.1158/1538-7445.AM2014-1796
Parents should remove risk factors to reduce asthma in children
Authors: D. Spurgeon
Journal: BMJ (2001)

Have a career related problem that needs answering? Can9t find the person to point you in the right direction? Log on to the Advice Zone for reliable medical careers advice. You can post a question or see if one of our 300 advisers has already answered a similar question. Here is a selection of questions and answers posted on the site <b>www.bmjcareers.com/advicezone</b>
Abstract 18440: Left Ventricular Epicardial Pacing Reduces Intramural Dyssynchrony in Myopathic Human Hearts: Implications for Biventricular Pacing
Authors: Paul Angaran, Stephane Masse, Krishnakumar Nair, Kwaku Poku, Talha Farid, Karthikeyan Umapathy, John Asta, Justin Mariani, Gopal Sivagangabalan, Kumaraswamy Nanthakumar
Journal: Circulation (2010)

Introduction: Intramural electrical activation during pacing has not been well-defined in human myopathic hearts. The aim of this study was to characterize the electrical activation patterns in hum...
PULMONARY TUBERCULOSIS OF THE INSANE
Authors: Joseph R. Blalock, James B. Funkhouser
Journal: Annals of Internal Medicine (1943)

Excerpt Refinements in roentgenological technic making possible the rapid, inexpensive chest survey of large groups have stimulated considerable interest in the old problem of tuberculosis among the insane. The authors have made a primary survey in Southwestern State Hospital and have derived certain impressions from their experience in the subsequent management of the tuberculous patients so segregated. The initial survey has been followed by similar studies of all patients admitted since the original survey. It is felt that those now engaged in this work, or who plan work of a similar character, may be interested in our findings and observations. RELATED
Abstract 615: TRPM8 channel as a novel molecular target in androgen-regulated prostate cancer cells
Authors: Swapna Asuthkar, Kiran Velpula, Eleonora Zakharian
Journal: Cancer Research (2014)

Abstract TRPM8 channels are highly expressed in prostate cancer cells but the physiological and pathological functions of TRPM8 in these cells are not known. In addition to prostate cancer (PC) cells, TRPM8 is expressed in sensory neurons where it acts as a sensor of cold. Recently, trpm8 has been identified as both an important gene regulated by androgens and a critical regulator of Ca2+ homeostasis. The androgen and its receptor (AR) are pivotal in the biology of sex hormone-regulated malignancies, with PC the most affected tumor. From the chromatin-immunoprecipitation (ChIP) analysis, we observed that an androgen response element (ARE) mediates androgen regulation of TRPM8. Further, using immunoprecipitation and calcium-imaging experiments, we identified that TRPM8 Ca+2 channels are functionally associated with androgens (testosterone and 5α-dihydrotestosterone) in the prostate. We also identified that unlike prostate cancer cell lines (LNCAP, PC3 and RWPE2) and normal prostate tissues, prostate tumor tissues (grade 1-4) showed high levels of TRPM8 which was predominantly localized as the plasma membrane protein at the tumor periphery. Of note, the decreased stabilization of TRPM8 on the plasma membrane was associated with increased expression of AR protein. These results suggest an important role of androgen signaling in trpm8 gene transcription corroborating to cancer progression and clinical lethality in prostate cancer. Citation Format: Swapna Asuthkar, Kiran Velpula, Eleonora Zakharian. TRPM8 channel as a novel molecular target in androgen-regulated prostate cancer cells. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 615. doi:10.1158/1538-7445.AM2014-615
Visual-evoked potential evidence of chiasmal hypoplasia11The views expressed in this publication are those of the authors and not necessarily those of the NHS Executive.
Authors: Dorothy A Thompson, Anthony Kriss, Kling Chong, Christopher Harris, Isabelle Russell-Eggitt, Fatima Shawkat, Brian G.R Neville, Wagih Aclimandos, David S.I Taylor
Journal: Ophthalmology (1999)
Abstract 1698: Identification of drugs with eribulin combinatorial activity that kill both eribulin-sensitive and eribulin-insensitive tumor cells
Authors: Toshimitsu Uenaka, Richard Rickles, Yasuhiro Funahashi, Ping Zhu, Jill M. Grenier, Janine Steiger, Nanding Zhao, Bruce A. Littlefield, Junji Matsui, Kenichi Nomoto
Journal: Cancer Research (2014)

Abstract Eribulin mesylate, a nontaxane microtubule dynamics inhibitor with a mechanism distinct from most other antitubulin therapeutics, is clinically used in the United States for treatment of certain patients with locally advanced or metastatic breast cancer. Eribulin has broad anticancer activity in a wide variety of preclinical cancer models; as a result, numerous clinical trials are ongoing to investigate efficacy in other non-breast tumor types. We have examined eribulin sensitivity in a panel of 25 human cancer cell lines representing a variety of tumor types albeit with a preponderance of breast and lung cancer cell lines. As expected, the cell lines vary in sensitivity to eribulin at clinically relevant concentrations. To identify combination drugs capable of increasing anticancer effects in patients already responsive to eribulin, as well as inducing de novo anticancer effects in non-responders, we performed a combinatorial high throughput screen to identify drugs that combine with eribulin to selectively kill tumor cells. Among other observations, we found that inhibitors of ErbB1/ErbB2 (lapatinib, BIBW-2992, erlotinib), MEK (E6201, trametinib), PI3K (BKM-120), mTOR (AZD 8055, everolimus), and PI3K/mTOR (BEZ 235), and a BCL2 family antagonist (ABT-263) show combinatorial activity with eribulin. In addition, antagonistic pairings with other agents, such as topoisomerase I inhibitors (topotecan hydrochloride), an HSP-90 inhibitor (17-DMAG), and gemcitabine and cytarabine, were also identified. In summary, the preclinical studies described here have identified several combination drugs that have the potential to either augment or antagonize eribulin's anticancer activity. Further elucidation of the mechanisms responsible for such interactions may be important for identifying valuable therapeutic partners for eribulin. Citation Format: Toshimitsu Uenaka, Richard Rickles, Yasuhiro Funahashi, Ping Zhu, Jill M. Grenier, Janine Steiger, Nanding Zhao, Bruce A. Littlefield, Junji Matsui, Kenichi Nomoto. Identification of drugs with eribulin combinatorial activity that kill both eribulin-sensitive and eribulin-insensitive tumor cells. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 1698. doi:10.1158/1538-7445.AM2014-1698
Implantation-Related Complications of Implantable Cardioverter-Defibrillators and Cardiac Resynchronization Therapy Devices
Authors: Johannes B. van Rees, Mihály K. de Bie, Joep Thijssen, C. Jan Willem Borleffs, Martin J. Schalij, Lieselot van Erven
Journal: Journal of the American College of Cardiology (2011)